Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity
about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuCD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancerImmunotherapy for prostate cancer: recent developments and future challengesSpecific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasisUse of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferationMonitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl esterAdoptive transfer of Mammaglobin-A epitope specific CD8 T cells combined with a single low dose of total body irradiation eradicates breast tumorsIdentification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cellsT cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.Rad52 deficiency decreases development of lung squamous cell carcinomas by enhancing immuno-surveillance.A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemiaLarge T Antigen-Specific Cytotoxic T Cells Protect Against Dendritic Cell Tumors through Perforin-Mediated Mechanisms Independent of CD4 T Cell HelpLangerhans cells as targets for immunotherapy against skin cancer.Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help.Dendritic cell-based vaccines: barriers and opportunitiesLAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responsesGeneration of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer.Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cellsAspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinomaPossible role of arginase-1 in concomitant tumor immunityAdoptive-cell-transfer therapy for the treatment of patients with cancerDNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potencyEpigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells.Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen.Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor TherapyThe Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer.Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection.Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progressionBooster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on primingEffects of depression on parameters of cell-mediated immunity in patients with digestive tract cancersConcomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.
P2860
Q21131200-AA0112F9-1795-4C6B-8790-B6500C39941FQ24540429-14035B7D-2C88-4337-8BED-A0B63B5002F4Q26749451-21F0E9DF-59C0-43F4-A845-9217E4A5D121Q26852388-A31EB149-6FEE-4271-A37F-C9E4C886DE24Q27310303-3A6A6F2D-DCB5-479C-AC2D-11FCBA451583Q28236025-AEB3D92C-D357-4DA9-AFF1-7C9174EC32DDQ28248444-75CCDFA8-F3F6-4A42-AA79-E352FC85D8D1Q28386603-593EBEE1-275D-4710-B7C3-42ADA7D70258Q33496761-1410000F-0D50-4564-B318-18BDA68D3D0AQ33530527-1A9FE2A4-263B-436C-B4D0-17F81F3EAF05Q33730129-5A7BBC79-4031-4594-B66B-5057671E3E0BQ33798257-3D69BF81-E057-415E-911C-D670E16CC9BFQ33849643-EFD72277-1207-4DA5-8C63-6ACE35DC4EB4Q33914233-A016B1D0-4E92-49BC-A2F3-9733992119D0Q34009436-45666602-BE84-4A52-9BD2-9BCD7F9AC57CQ34022415-B196C8B0-EFBA-40CD-B6A7-42D9F054A398Q34041058-BAAD8101-2ED2-4DCF-B979-9BAADCA9020EQ34661797-5B634595-E8A3-4ED0-AB6A-4835C317D9C0Q34700552-EC5851E2-8100-40B2-9F5D-F3568FCBDF5DQ34732491-6C463392-E2CB-4A20-A4A5-C837DECF4891Q34803707-38895F2A-F97E-4B49-AC9B-6E1DD65668CCQ34934320-B2405080-B034-4020-8483-1F749574F4FBQ35071850-ED50442A-037F-4491-9E0B-BA75E7EC66DEQ35091441-86CA609D-E953-4933-994A-20FB1D115B44Q35116475-8BA2C53C-EB4E-4991-B37A-4AE5ACF4A917Q35210008-36C005BB-F99C-485A-937C-687C1D70054EQ35210348-28D402D9-DFE1-4B50-AA1F-F5890C91CE7DQ35234948-41F25AD6-FDDE-44A6-8A34-98A6D66848AFQ35628806-A5E25196-82FE-43E3-A666-D78A4B66FE04Q35799065-49EE6F6F-5194-46C7-94FE-C5FE458BA7F7Q35982675-8E6CE408-183F-4DB3-9ED1-38BC97DC627EQ36031036-E8F9E698-467A-455C-AE4A-1F1729F4365BQ36249440-63597C71-8218-4640-9D46-7B365008C275Q36349514-82D02423-B407-47F1-B71B-2535AE1E1F1AQ36382255-94F7CAF7-54BB-4A1F-876B-E17738023E77Q36399636-400CBA82-65E9-4526-9326-599593EA8DE9Q36399807-2715A4A1-EBB9-4131-B8F1-26D734AF0D8AQ36446446-4A757D11-1513-42F0-A65C-084952BC57E8Q36474422-3C8C3A59-AA73-41F7-B08B-5F93DB2172AAQ36567697-038256DD-CB44-4D63-9E6B-86591BCD262A
P2860
Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Tumor-specific CD4+ T cells ha ...... L mediated anti-tumor immunity
@ast
Tumor-specific CD4+ T cells ha ...... L mediated anti-tumor immunity
@en
Tumor-specific CD4+ T cells ha ...... L mediated anti-tumor immunity
@nl
type
label
Tumor-specific CD4+ T cells ha ...... L mediated anti-tumor immunity
@ast
Tumor-specific CD4+ T cells ha ...... L mediated anti-tumor immunity
@en
Tumor-specific CD4+ T cells ha ...... L mediated anti-tumor immunity
@nl
prefLabel
Tumor-specific CD4+ T cells ha ...... L mediated anti-tumor immunity
@ast
Tumor-specific CD4+ T cells ha ...... L mediated anti-tumor immunity
@en
Tumor-specific CD4+ T cells ha ...... L mediated anti-tumor immunity
@nl
P2093
P3181
P1476
Tumor-specific CD4+ T cells ha ...... L mediated anti-tumor immunity
@en
P2093
B F Kinnear
B W Robinson
E J Collins
J J Frelinger
P304
P3181
P356
10.4049/JIMMUNOL.165.11.6047
P407
P577
2000-12-01T00:00:00Z